Under scheme of amalgamation
The Board of Lincoln Pharmaceuticals at its meeting held on 05 October 2021 has approved the allotment of 29,728 equity shares of Rs 10 each of the company pursuant to the scheme of amalgamation of Lincoln Parenteral (transferor company) and Lincoln Pharmaceuticals (transferee company) with their respective shareholders and creditors.Further, 98,58,438 equity shares of transferor company held by the Company (transferee company) shall be cancelled without any act, deeds or instrument.
Accordingly, post the allotment of shares, the paid up equity share capital of the company has increased to Rs 20,02,97,280 dividend into 2,00,29,728 equity shares of Rs 10 each.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app